Sign in

Private company

Zosano Pharma Corp

American pharmaceutical preparations company based in Fremont, no longer active2

In its 2022 annual report the company says: “Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics and other bioactive molecules to patients using our proprietary transdermal microneedle system. Our System is designed to facilitate rapid drug absorption into the bloodstream, and to provide an improved pharmacokinetic profile compared to original dosage forms.”54

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersFremont, United States2
  • Incorporated inDE3
  • Business address34790 Ardentech Court, Fremont, Ca 945553
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI5493006NX8EN835MNW492
  • StatusInactive2
  • LEI statusRetired2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 51010272

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-4016.8%Operating margin4
-3812.1%Net margin4
250.4%Revenue growth, 20214
-90.8%Return on equity4
0.00×Debt to equity4
-$33.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue4¢$796.0K
  • Research and development96¢$21.0M
  • Interest1¢$189.0K

Out of $785.0K in revenue.4 The company lost money this year.

Financial statements

Revenue567894$785.0K in 2021+151% since 2015
0$200.0K$400.0K$600.0K$800.0K2015: $313.0K$313.0K20152016: $0$020162017: $0$020172018: $0$020182019: $0$020192020: $224.0K$224.0K20202021: $785.0K$785.0K2021+250%
Operating income567894-$31.5M in 2021+20% since 2015
-$40.0M-$30.0M-$20.0M-$10.0M02015: -$26.4M-$26.4M20152016: -$28.6M-$28.6M2016+9%2017: -$28.4M-$28.4M2017−1%2018: -$35.4M-$35.4M2018+25%2019: -$37.2M-$37.2M2019+5%2020: -$32.8M-$32.8M2020−12%2021: -$31.5M-$31.5M2021−4%
Net income567894-$29.9M in 2021+5% since 2015
-$40.0M-$30.0M-$20.0M-$10.0M02015: -$28.4M-$28.4M20152016: -$29.8M-$29.8M2016+5%2017: -$29.1M-$29.1M2017−2%2018: -$35.4M-$35.4M2018+21%2019: -$37.6M-$37.6M2019+6%2020: -$33.4M-$33.4M2020−11%2021: -$29.9M-$29.9M2021−10%
Fiscal year2015201620172018201920202021
Revenue$313.0K5$06$07$08$09$224.0K4$785.0K4
Cost of revenue$09$171.0K4$796.0K4
Research and development$20.4M5$20.5M6$20.1M7$25.5M8$25.4M9$21.6M4$21.0M4
Operating expenses$32.3M4
Operating income-$26.4M5-$28.6M6-$28.4M7-$35.4M8-$37.2M9-$32.8M4-$31.5M4
Interest$817.0K7$379.0K8$523.0K9$719.0K4$189.0K4
Income before tax-$29.9M4
Income tax$05$06$07$08$09$04$04
Net income-$28.4M5-$29.8M6-$29.1M7-$35.4M8-$37.6M9-$33.4M4-$29.9M4
Earnings per share-$0.494-$0.274
Earnings per share (diluted)-$0.494-$0.274
Shares (weighted, basic)112.1M shares4
Shares (weighted, diluted)112.1M shares4

Compare Zosano Pharma Corp with another company

Corporate structure

Zosano Pharma Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Zosano Pharma Corp

  • Zosano Pharma Corp Fremont, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Zosano Pharma Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Accumulated depreciation$30.0M4 Dec 31, 2021$28.2M4 Dec 31, 2020+6.2%
Property and equipment, net$32.6M4 Dec 31, 2021$30.9M4 Dec 31, 2020+5.3%
Operating-lease assets (leased space)$3.8M4 Dec 31, 2021$4.9M4 Dec 31, 2020−23.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.0M4 Dec 31, 2021$35.3M4 Dec 31, 2020−68.7%

Leadership

Who has led Zosano Pharma Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Vikram Lamba2015
  2. Konstantinos Alataris2016–2017
  3. Steven Lo2019–2022

President

  1. Vikram Lamba2015
  2. Konstantinos Alataris2015–2017

Chief financial officer

  1. Winnie Wing-Kei Tso2015–2017
  2. Georgia Erbez2016–2017
  3. Gregory David Kitchener2018–2019
  4. Christine Matthews2020–2022

Chief operating officer

  1. Nandan Oza2015
20202025
Board members and other officers (21)

Former names

  • ZP Holdings IncSep 20, 2013 to May 13, 20143

Timeline

  1. Jun 3, 20228-K Listing notice or transfer38
  2. Jun 2, 20228-K Ended a material agreement; Bankruptcy or receivership; Other events39
  3. May 18, 20228-K Executive or director change40
  4. May 13, 20228-K Results of operations; Executive or director change41
  5. May 5, 20228-K Executive or director change42
  6. Apr 29, 20228-K Other events43
  7. Apr 11, 20228-K Change to shareholders' rights; Bylaws or fiscal year changed; Shareholder vote44
  8. Mar 17, 20228-K Results of operations45
  9. Feb 18, 20228-K Other events46
  10. Feb 9, 20228-K Entered a material agreement; Other events47
  11. Jan 31, 20228-K Other events48
  12. Jan 24, 20228-K Other events49
  13. Oct 23, 2019New chief executive Steven Lo becomes CEO12
  14. Feb 4, 2016New chief executive Konstantinos Alataris becomes CEO13
  15. Jan 26, 2015New chief executive Vikram Lamba becomes CEO14
  16. Jan 26, 2012Founded Zosano Pharma Corp is founded2

Calendar

When it reported results

  1. May 13, 2022Reported quarterly or annual results41
  2. Mar 17, 2022Reported quarterly or annual results45
  3. Nov 10, 2021Reported quarterly or annual results50

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

42 filings to the SEC since October 2021: 2 annual reports, 2 quarterly reports, 20 major events, 11 insider forms, 1 large holders, 6 other. The latest 20:

  1. Jun 7, 20224 FORM 4 SUBMISSION EDGAR
  2. Jun 7, 20224 FORM 4 SUBMISSION EDGAR
  3. Jun 3, 20228-K EDGAR
  4. Jun 2, 20228-K EDGAR
  5. May 18, 2022SC 13G SCHEDULE 13G EDGAR
  6. May 18, 20228-K EDGAR
  7. May 13, 202210-Q EDGAR
  8. May 13, 20228-K EDGAR
  9. May 5, 20228-K EDGAR
  10. Apr 29, 202210-K/A EDGAR
  11. Apr 29, 20228-K EDGAR
  12. Apr 11, 20228-K EDGAR
  13. Apr 1, 20224 EDGAR
  14. Apr 1, 20224 EDGAR
  15. Apr 1, 20224 EDGAR
  16. Apr 1, 2022S-8 EDGAR
  17. Mar 17, 202210-K EDGAR
  18. Mar 17, 20228-K EDGAR
  19. Feb 25, 2022DEF 14A EDGAR
  20. Feb 18, 20228-K EDGAR

The 42 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

6 open-market trades by officers, directors and large owners since October 2021: 0 buys and 6 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 6, 2022Matthews ChristineChief Financial OfficerSale82$0.71$58Form 4
Jun 6, 2022Lo StevenChief Executive OfficerSale442$0.71$314Form 4
Mar 31, 2022Matthews ChristineChief Financial OfficerSale8,116$0.21$1.7KForm 4
Mar 31, 2022KELLERMAN DONALD JVP, Clinical Dev & Med AffairsSale4,006$0.21$841Form 4
Mar 31, 2022Lo StevenChief Executive OfficerSale23,633$0.21$5.0KForm 4
Nov 23, 2021GREATHOUSE KENNETHDirectorSale10,000$0.60$6.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$1.6M 2020–2020
Money received by yearMoney received by year, 2020–2020: $1.6M in all. PPP loans $1.6M.$0$500K$1M$1.5M$2M2020 · PPP loans: $1.6M2020
Figures by year
YearPPP loansTotal
2020$1.6M$1.6M

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA52. Matched to this company by name and state.

  1. Apr 15, 2020$1.6M PPP loan (first draw) from Silicon Valley Bridge Bank NA52To ZOSANO PHARMA CORPORATION, Fremont CA; $1.6M forgiven Jun 11, 2021

SEC filer profile

How Zosano Pharma Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARZosano Pharma Corp1
  • CIK0001587221
  • Employer ID (EIN)45-44883601
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address34790 Ardentech Court, Fremont, CA 945551
  • Phone510-745-12001
  • Shares outstanding4,902,260 as of May 11, 202210
  • Public float$105.0M as of Jun 30, 202153
  • On EDGAR sinceSep 20, 20131
  • Filings511 in all: 8-K (147), 4 (131), 3 (29), 10-Q (22), SC 13G (21), CORRESP (17), SC 13G/A (15), S-1/A (14)1
    All 38 form types

    424B5 (13), UPLOAD (13), DEF 14A (10), 10-K (8), EFFECT (8), S-8 (7), D (6), DEFA14A (6), 4/A (5), 8-K/A (5), S-1 (4), S-3 (4), 10-K/A (2), 424B3 (2), 424B4 (2), CT ORDER (2), FWP (2), PRE 14A (2), SC TO-I/A (2), SEC STAFF LETTER (2), 25-NSE (1), 3/A (1), 424B1 (1), 8-A12B (1), CERTNAS (1), DEFR14A (1), DRS (1), NT 10-Q (1), POS EX (1), SC TO-I (1)

  • Latest filingsAnnual report (10-K) Mar 17, 2022
    Quarterly report (10-Q) May 13, 2022
    Proxy statement (DEF 14A) Feb 25, 2022
    Latest 8-K (8-K) Jun 3, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
    SEC EDGAROther events
  44. 44
  45. 45
  46. 46
    SEC EDGAROther events
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
    SEC EDGAROther events
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54